Unlocking CXL’s Molecular Mysteries – With Mice
Swiss researchers have developed methods for performing corneal crosslinking with riboflavin and corneal biomechanical testing in mice – opening up the world of transgenics and molecular testing.
Farhad Hafezi |
Corneal collagen cross-linking (CXL) with UV-A illumination and riboflavin is a useful way of increasing corneal stiffness to halt the progression of corneal ectatic disorders like keratoconus. But there’s still much to be learned about the cellular and molecular events that take place during CXL and afterwards – and plugging those gaps in knowledge has been difficult. Ex vivo testing fails to provide an accurate picture because hydration and preservation processes after enucleation change the properties of the tissue and affect the accuracy of the testing, and to date, only indirect (and often inaccurate) methods of determining the efficacy of CXL in vivo exist. But change is afoot; a group of Swiss researchers led by Farhad Hafezi have tackled the problem by successfully establishing a CXL procedure, in vivo, in mice and then developing tools to accurately measure biomechanical changes in the mouse cornea that are induced by the procedure (1).
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.